Kuchuluka kwa Ozempic kumatanthauza kuwongolera bwino matenda amtundu wa 2

Novo Nordisk lero yalengeza kuti US Food and Drug Administration (FDA) yavomereza jekeseni wa 2 mg wa Ozempic® (semaglutide), jekeseni wa glucagon ngati peptide-1 (GLP-1) kamodzi pa sabata yomwe ikuwonetsedwa pamodzi ndi zakudya ndi masewera olimbitsa thupi. kukonza shuga m'magazi mwa akuluakulu omwe ali ndi matenda a shuga a 2 komanso kuchepetsa chiopsezo cha zochitika zazikulu za mtima monga matenda a mtima, kupwetekedwa mtima kapena imfa kwa akuluakulu omwe ali ndi matenda a shuga a 2 komanso matenda a mtima omwe amadziwika bwino.2 Ozempic® si mankhwala ochepetsa thupi, koma akhoza thandizani anthu kuchepetsa thupi. Ozempic® ipezeka m'miyeso itatu yochizira (0.5 mg, 1 mg, ndi 2 mg) kuthandiza anthu omwe ali ndi matenda a shuga amtundu wa 2 kukwaniritsa cholinga chawo cha shuga (A1C), tsopano kuphatikiza omwe ali ndi A1C yapamwamba omwe sanathe kukwaniritsa cholinga chawo. Cholinga cha A1C.

Mu pulogalamu yachipatala ya Ozempic® SUSTAIN phase 3, mpaka 73% ya anthu omwe ali ndi matenda a shuga a mtundu wa 2 omwe amathandizidwa ndi Ozempic® 1 mg adatsitsa shuga wawo wamagazi ndipo adafika ku American Diabetes Association chandamale <7%.3-5 Ngakhale izi, pali akadali anthu omwe sali pa mlingo wawo wa shuga wamagazi.1,4-10 Ozempic® 2 mg amathandiza omwe amafunikira kuwongolera kowonjezera kwa glycemic ndipo ndi njira yofunikira kwa odwala ndi opereka chithandizo chamankhwala chopitilira mtundu wa 2 shuga.

"Mtundu wa 2 shuga ndi matenda ovuta omwe amatha kupita patsogolo pakapita nthawi ngakhale atakhala kuti akuwongolera ndi mankhwala, zakudya komanso masewera olimbitsa thupi," adatero Dr Juan Pablo Frias, mkulu wa zachipatala ku Velocity Clinical Research, Los Angeles ndi wofufuza wamkulu wa SUSTAIN FORTE, kuyesa kwachipatala kwa gawo 3 komwe kumathandizira kuvomereza kwa Ozempic® 2 mg. "Pokhala ndi chitetezo chotsimikizirika komanso chothandiza, Ozempic® imathandizira kuwongolera shuga m'magazi ndikuchepetsa chiopsezo chachikulu cha matenda amtima kwa akuluakulu omwe ali ndi matenda a shuga a 2 komanso matenda amtima odziwika, kuphatikiza kungathandize odwala ambiri kuti achepetse thupi. Ndi mlingo wa 2 mg, tili ndi njira yowonjezerapo kuti odwala azikhalabe ndi mankhwala omwewo ngakhale shuga wawo wamagazi angafunike kusintha. "

Mu mayesero a SUSTAIN FORTE, anthu omwe ali ndi chiwerengero choyambira A1C cha 8.9% omwe amathandizidwa ndi Ozempic® 2 mg adapeza kuchepa kwakukulu komanso kwakukulu kwa shuga wamagazi a 2.1% pa sabata 40 poyerekeza ndi 1.9% ndi Ozempic® 1 mg (P<0.01 ) .1 Mu phunziro lomwelo, anthu omwe ali ndi kulemera koyambira kwa 219 lb omwe amathandizidwa ndi Ozempic® 2 mg adataya 14.1 lb poyerekeza ndi kulemera kwa 12.5 lb ndi Ozempic® 1 mg; kusiyana sikunali kofunikira powerengera. Pamiyeso yonse iwiri ya Ozempic®, panalibe zizindikiro zatsopano zachitetezo zomwe zidadziwika.1 Zovuta zofala kwambiri zinali za m'mimba.1 Zovuta za m'mimba zimachitika pafupipafupi pakati pa odwala omwe amalandila Ozempic® 2 mg (34.0%) vs Ozempic® 1 mg (30.8% ).1

"Ozempic® ili pa chithandizo chothandizira kusintha kwa Novo Nordisk pakuthandizira matenda a shuga, ndi anthu oposa milioni imodzi omwe ali ndi matenda a shuga a mtundu wa 2 ku United States omwe amathandizidwa ndi Ozempic®," adatero Doug Langa, wachiwiri kwa pulezidenti, North America ntchito ndi pulezidenti. a Novo Nordisk Inc. "Pokhala ndi Ozempic® yomwe tsopano ikupezeka mu mphamvu zosiyanasiyana za dosing, tili ndi chiyembekezo kuti titha kuthandiza anthu ambiri omwe ali ndi matenda a shuga a mtundu wa 2 omwe amafunikira kuwongolera shuga wambiri kuti adziwe ubwino wa Ozempic®."  

Novo Nordisk ikuyembekeza kukhazikitsa Ozempic® 2 mg ku United States posachedwa. Ozempic® 2 mg idavomerezedwa ndi Swiss Medic mu Seputembara 2021 ndikutsatiridwa ndi Health Canada ndi European Medicines Agency mu Januware 2022.